Erenumab
CGRP receptor antagonist
Also sold as Aimovig
Cumulative therapeutic effect
Migraine-prevention benefit assessed after 3 monthly doses.
Effect timeline
Approximate single-dose timeline. Onset shows when effects are felt; Tmax shows when blood levels peak.
Notes
Monthly preventive injection.
Erenumab is a cgrp receptor antagonist given by the subq route. It's typically used in the migraine category.
After one subq dose you'd typically start noticing the effect in 7 days – 4 weeks. The drug reaches its highest blood level in about 6 days, and a single dose usually keeps working for around 4 weeks.
Take consistently — the full benefit builds over time, not from a single dose. Long-acting — take at roughly the same time each day for steady levels.
Don't combine with other products in the same drug class without checking with a pharmacist. Stop and seek medical advice if you have an unexpected reaction, severe side effect, or symptoms that don't improve.
All timings are approximate population ranges for a typical adult dose. Individual response varies with age, genetics, formulation, food, and other medications.
Typical dosing
Source: OpenFDA drug label · adult dosing unless noted
Doses vary by age, weight, kidney/liver function, and indication. Don't change your dose without talking to your prescriber.
Verify on the exact label used:DailyMed search·OpenFDA record
Side effects & warnings
Source: OpenFDA drug label
Verify on the exact label used:DailyMed search·OpenFDA record
Educational information only — not medical advice. Times vary by person, dose, and formulation. Always consult a doctor or pharmacist for personal guidance.